Show simple item record

dc.contributor.authorAparicio, Cristina
dc.contributor.authorBelver Jiménez, Marina
dc.contributor.authorEnríquez, Lucía
dc.contributor.authorEspeso, Francisco
dc.contributor.authorNúñez Llorente, Lucía 
dc.contributor.authorSánchez García, Ana María de los Ángeles 
dc.contributor.authorFuente García, Miguel Ángel de la 
dc.contributor.authorGonzález-Vallinas Garrachón, Margarita 
dc.date.accessioned2023-05-08T12:13:01Z
dc.date.available2023-05-08T12:13:01Z
dc.date.issued2021
dc.identifier.citationInternational Journal Molecular Science, 2021, vol. 22, n. 21, 11781es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/59536
dc.descriptionProducción Científicaes
dc.description.abstractColorectal cancer (CRC) is a global public health problem as it is the third most prevalent and the second most lethal cancer worldwide. Major efforts are underway to understand its molecular pathways as well as to define the tumour-associated antigens (TAAs) and tumour-specific antigens (TSAs) or neoantigens, in order to develop an effective treatment. Cell therapies are currently gaining importance, and more specifically chimeric antigen receptor (CAR)-T cell therapy, in which genetically modified T cells are redirected against the tumour antigen of interest. This immunotherapy has emerged as one of the most promising advances in cancer treatment, having successfully demonstrated its efficacy in haematological malignancies. However, in solid tumours, such as colon cancer, it is proving difficult to achieve the same results due to the shortage of TSAs, on-target off-tumour effects, low CAR-T cell infiltration and the immunosuppressive microenvironment. To address these challenges in CRC, new approaches are proposed, including combined therapies, the regional administration of CAR-T cells and more complex CAR structures, among others. This review comprehensively summarises the current landscape of CAR-T cell therapy in CRC from the potential tumour targets to the preclinical studies and clinical trials, as well as the limitations and future perspectives of this novel antitumour strategy.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectMedicinaes
dc.subjectOncologíaes
dc.subjectCancer Researches
dc.subject.classificationColorectal canceres
dc.subject.classificationCAR-T cellses
dc.subject.classificationImmunotherapyes
dc.subject.classificationNeoantigenses
dc.subject.classificationCáncer colorrectales
dc.subject.classificationCélulas CAR-Tes
dc.subject.classificationInmunoterapiaes
dc.subject.classificationNeoantígenoses
dc.titleCell therapy for colorectal cancer: The promise of chimeric antigen receptor (CAR)-T cellses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2021 The Authorses
dc.identifier.doi10.3390/ijms222111781es
dc.relation.publisherversionhttps://www.mdpi.com/1422-0067/22/21/11781es
dc.identifier.publicationfirstpage11781es
dc.identifier.publicationissue21es
dc.identifier.publicationtitleInternational Journal of Molecular Scienceses
dc.identifier.publicationvolume22es
dc.peerreviewedSIes
dc.description.projectJunta de Castilla y León (CCVC8485)es
dc.description.projectInstituto de Salud Carlos III (RD16/0011/0003)es
dc.identifier.essn1422-0067es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones
dc.subject.unesco3201.01 Oncologíaes


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record